References
- Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. Obesity at diagnosis and prostate cancer prognosis and recurrence risk following primary treatment by radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1917–25. pii: cebp.0488.2019. doi:10.1158/1055-9965.EPI-19-0488
- Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol. 2017;27(5):415–21. doi:10.1097/MOU.0000000000000424
- Schwarzman LS, Pagani RL, Ohlander SJ, Mima M, Abern MR, Andriole GL, Freedland SJ, Moreira DM. Diagnostic properties of total and free prostate-specific antigen to predict overall and clinically significant prostate cancer among men with low testosterone and prior negative biopsy. Urology. 2020;137:97–101. pii: S0090-4295(19)30972-0. doi:10.1016/j.urology.2019.11.004
- Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M, Donovan J, Hamdy FC, Neal DE, Martin RM. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes Control. 2016;27(12):1465–74. doi:10.1007/s10552-016-0827-1
- Gomes JL, Fernandes T, Soci UP, Silveira AC, Barretti DL, Negrão CE, Oliveira EM. Obesity Downregulates MicroRNA-126 inducing capillary rarefaction in skeletal muscle: effects of aerobic exercise training. Oxid Med Cell Longev. 2017;2017:2415246. doi:10.1155/2017/2415246
- Hijmans JG, Diehl KJ, Bammert TD, Kavlich PJ, Lincenberg GM, Greiner JJ, Stauffer BL, DeSouza CA. Influence of overweight and obesity on circulating inflammation-related microRNA. MIRNA. 2018;7(2):148–54. doi:10.2174/2211536607666180402120806
- Hua Y, Liang C, Miao C, Wang S, Su S, Shao P, Liu B, Bao M, Zhu J, Xu A, et al. MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9. Oncol Lett. 2018;15(6):9051–60. doi:10.3892/ol.2018.8528
- Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, et al. Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget. 2017;8(21):35376–89. doi:10.18632/oncotarget.15686
- Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 2011;71(3):232–40. doi:10.1002/pros.21237